| DAIC

$Neovasc’s Innovative Reducer System will target the estimated $5 billion refractory angina market$

January 19, 2023

Abbott Receives FDA Approval for Navitor TAVI System

January 19, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest-…

Grants will provide increased opportunity for clinical research within interventional cardiology and address disparities in care

January 18, 2023

SCAI Announces Recipients of Early Career Research Grants

January 18, 2023 — the Society for Cardiovascular Angiography & Interventions (SCAI) announced four recipients of…

Phone calls from a nurse may improve survival for patients treated for heart failure, according to a new study by investigators from the Smidt Heart Institute at Cedars-Sinai.

January 18, 2023

Calling Patients After Heart Failure May Save Lives

January 18, 2023 — Phone calls from a nurse may improve survival for patients treated for heart failure, according to a…

According to the U.S. Centers for Disease Control and Prevention (CDC), one person dies every 37 seconds in the United States from cardiovascular disease.

By Christine Book

January 18, 2023

Rising Demand for Cardiac CT Positions Market for Major Growth

According to the U.S. Centers for Disease Control and Prevention (CDC), one person dies every 37 seconds in the United…

The risk of hypertension increases significantly with orthostatic circulatory disorders.

January 17, 2023

RUDN University Doctors Tested a Novel Approach to Detecting Future Arterial Hypertension in Healthy People

January 17, 2023 — Arterial hypertension(AH), or high blood pressure, can be prevented if diagnosed pre-clinically on…

RUDN doctors analyzed the latest research on the use of RNA for the treatment and diagnosis of ischemic stroke. And, although it is too early to talk about clinical use, one of the RNAs turned out to be both a promising biomarker and a therapeutic target

January 17, 2023

RNA Will Help Treat and Diagnose Ischemic Stroke

January 17, 2023 — Ischemic stroke, or cerebral infarction, ranks first in prevalence among diseases that lead to death…

January 16, 2023

Getting to the Heart of Chemotherapeutic Cardiotoxicity

January 16, 2023 — On any given Tuesday, you will find Brian C. Jensen, MD, cardiologist and physician-scientist,…

Medical center signs agreement to acquire the Company’s digital signal processing technology for arrhythmia care

January 13, 2023

BioSig Executes Agreement with Bellin Health for the Acquisition of its PURE EP Technology

January 13, 2023 — BioSig Technologies, Inc., an advanced digital signal processing technology company delivering…

Patients seen at transplant centers had almost 80% higher odds to receive “bridge-to-transplant” designation

January 13, 2023

Medicare Policy Change Could Increase Inequity in Heart Transplant Access, Study Finds

January 13, 2023 — A change to Medicare policy surrounding heart transplant may lead to increased inequities in access…

ASNC releases comprehensive tool for assessing quality, setting meaningful goals, improving patient care in SPECT MPI laboratories

January 13, 2023

New Guide Will Change How Cardiac Imagers Approach Quality Improvement

January 13, 2023 — Nuclear stress testing performed with single-photon emission computed tomography (SPECT) is the most…

ADVANCE Trial compares sac regression in the Medtronic Endurant II/IIs stent graft system and the Gore® Excluder AAA Device Family systems

January 12, 2023

Medtronic Announces First Enrollment in Head-to-head Global Randomized Trial Evaluating Durability of Endovascular Aneurysm Repair

January 12, 2023 — Medtronic announced the first patient enrollment in the ADVANCE Trial, a head-to-head randomized…

SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions.

January 12, 2023

MedAlliance Selution SLR is the First DEB to Receive Coronary de novo IDE Approval, its Fourth FDA IDE DEB Approval

January 12, 2023 — Selution SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA…

Alameda, CA-based global healthcare company Penumbra has announced Food & Drug Administration (FDA) clearance and launch of Lightning Flash, which the company reports is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus.

January 11, 2023

FDA Clearance and Launch Granted to Penumbra Mechanical Thrombectomy System

January 11, 2023 — The Alameda, Calif.-based global healthcare company Penumbra has announced U.S. Food & Drug…

Phase 2 trials underway with ninerafaxstat in three cardiovascular indications; multiple data read-outs expected in 2023

January 11, 2023

Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction

January 11, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies…

January 11, 2023

Shockwave Intravascular Lithotripsy-assisted TMVR Shows Promise for Patients with Severe Stenosis and Regurgitation

January 11, 2023 — In recent years, transcatheter mitral valve replacement (TMVR) treatment and technology has evolved…

A Rutgers analysis of U.S. stroke deaths from 1975 to 2019 has found both a dramatic decline and the potential for an important resurgence.

January 11, 2023

After 40 Years of Decline, Stroke Death Rates Are Rising Again

January 11, 2023 — A Rutgers analysis of U.S. stroke deaths from 1975 to 2019 has found both a dramatic decline and the…

CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.

January 09, 2023

CinCor Pharma to be Acquired by AstraZeneca

January 9, 2023 — CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under…

$TGCV is an emerging cardiovascular disorder characterized by diffuse narrowing coronary atherosclerosis with triglyceride (TG) deposition caused by defective intracellular lipolysis. TGCV is an often-undiagnosed condition in patients who are resistant to standard therapies. Panels A and B concern two patients in their 60s with refractory angina pectoris and diabetes mellitus. After being diagnosed with TGCV, they started dietary intake of tricaprin. Their symptoms improved within a couple of months. Follow-$

January 09, 2023

A Dietary Supplement Leads to Remarkable Regression in Atherosclerotic Lesions

January 9, 2023 — When we were little, our parents told us to take our vitamins so we could grow big and strong. Now,…

January 09, 2023

ReCor Medical Names Lara Barghout President and Chief Executive Officer

January 9, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the…

NIH-supported study finds no serious complications following rare immune condition, multisystem inflammatory syndrome (MIS-C)

January 06, 2023

COVID-19 Vaccine for Children After MIS-C Appears Safe

January 6, 2023 — A study of children and adolescents who received a COVID-19 vaccination following multisystem…